Released in October 2019, CRASH-3 is the latest trial exploring the benefits of tranexamic acid, this time in traumatic brain injury. The bottom line: TXA hasn't been shown to reduce mortality.
The encouraging findings from this study? Medicaid expansion was successful in that repeat users shifted their ED use toward higher acuity conditions – that is, conditions for which EDs were designed.